How does the speaker characterize the approval of ropeginterferon for essential thrombocythemia?
Practice-changing, because it is the first interferon shown to cause molecular responses in ET
Practice-affirming, because MPN specialists have long used other interferon formulations in ET and have already seen deep molecular responses
Of limited relevance, because interferons only control blood counts and have no effect on the underlying disease